Page 212 - ebook HCC

PROGRAMME
GENEVA, SWITZERLANDA, SWITZERLAND
EASL HCC SUMMITHCC SUMMIT
211
210 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEV EASL 211
210
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C10
PROSPECTIVE EVALUATION OF THE
CORRELATION BETWEEN HEMOSTATIC STATUS
AND INCIDENCE OF PORTAL VEIN THROMBOSIS
IN PATIENTS WITH LIVER CIRRHOSIS AND
HEPATOCELLULAR CARCINOMA

Alberto Zanetto , Alberto Ferrarese , Alessandro Vitale , Umberto Cillo , Platelet count was significantly increased in HCC patients compared to non-HCC patients,
1
1
2
2
Kryssia-Isabel Rodriguez , Mariangela Fadin , Sabrina Gavasso , Claudia Radu , especially in Child Class A subjects. Patients with HCC showed significantly lower
3
3
1
3
Paola Zerbinati , Paolo Simioni , Fabio Farinati , Giacomo Germani , clotting time and maximum clot formation at ROTEM compared to healthy controls. The
1
4
3
3
Francesco Paolo Russo , Patrizia Burra , Marco Senzolo 1 hypercoagulable state was present even when HCC patients were compared to cirrhotics
1
1
1 Multivisceral Transplant Unit, Department of Surgical, Oncological and without HCC, and was more evident when performing a subgroup analysis of Child Class
Gastroenterological Sciences, Hepatobiliary Surgery and Liver Transplantation Unit, A patients, with statistically significant differences in MCF EXTEM/NATEM e CFT NATEM.
2
3
Padua University Hospital, Department of Cardiologic, Thoracic, and Vascular Sciences One-year-incidence of PVT was 19,5% (8/41) and 5.7% (2/35) in HCC and non-HCC
, Gastroenterology, Department of Surgical, Oncological and Gastroenterological patients, respectively (p=0,04). In the HCC group, 4/8 PVT occurred in patients in Child
4
Sciences, Padua University Hospital, Padova, Italy Class A. Fibrinogen test of ROTEM, MCF and AUC were statistically elavated in HCC
patients who later developed PVT
Corresponding author’s e-mail: alberto.zanetto@yahoo.it
Conclusions: Cirrhotics with HCC demonstrate a prothrombotic hemostatic balance
resulting in an increased risk of PVT development. ROTEM seems to be a sensitive
Introduction: Studies which explore the hypercoagulable state associated with neoplastic method to identify hypercoagulability, that would otherwise be undetected by routine
disease and its correlation with the risk of developing portal vein thrombosis (PVT) in laboratory testing. Further investigations are needed to determine whether patients with
patients with hepatocellular carcinoma (HCC) are lacking. HCC should receive prophylactic anticoagulation for PVT prevention.
Aims: The aim of the present study was to evaluate the thrombophilic role of HCC in
cirrhotics and to correlate coagulation profile of these patients with the incidence of
CLINICAL POSTER ABSTRACTS for thromboelastometry (ROTEM). All patients underwent: ROTEM, platelet count, CLINICAL POSTER ABSTRACTS
PVT. Methods: cirrhotic patients with and without HCC were prospectively enrolled
in the study. Age- and sex-matched healthy individuals constituted the control group
determination of prothrombin time and of levels of pro and anticoagulation factors. During
follow-up, PVT onset in both patients with and without HCC was recorded
Results: 76 cirrhotics, 41 with HCC and 35 without HCC, were included. Forty-eight
healthy volunteers were included as the control group. Volume of active HCC was >5 cm
3
in 18 patients. Levels of pro and anticoagulation factors were similar between patients with
and without HCC, but fibrinogen was increased in HCC patients with active volume >5cm
3
HCC compared to those with ≤5cm HCC bulk (348,72mg/dL±124,06mg/dL vs 237,64mg/
3
dL±99,18mg/dL) and to cirrhotics without HCC (260,57mg/dL±126,07mg/dL) (p=0,006).